Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy

Urol Int. 2008;80(4):451-3. doi: 10.1159/000132708. Epub 2008 Jun 27.

Abstract

A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy. After sorafenib treatment and before surgery a new CT scan confirmed the presence of a 9.0 cm in diameter solid mass in the left kidney but a reduction in thrombus extension, limited to the left renal vein. At histological examination after radical nephrectomy, over 90% of the renal mass was substituted by necrotic tissue.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Benzenesulfonates / administration & dosage*
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / therapy*
  • Chemotherapy, Adjuvant
  • Follow-Up Studies
  • Humans
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy*
  • Male
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Neoplastic Cells, Circulating / drug effects
  • Neoplastic Cells, Circulating / pathology*
  • Nephrectomy* / methods
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / administration & dosage*
  • Risk Assessment
  • Sorafenib
  • Treatment Outcome
  • Vena Cava, Inferior / pathology*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib